73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
uniQure NV
Open
22.62 3.01
Overview
Share price change
24h
Min
21.56
Max
22.57
Income | -43M -81M |
|---|---|
Sales | -1.6M 3.7M |
Profit margin | -2,175.871 |
Employees | 209 |
EBITDA | -7.7M -52M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +125.18% upside |
Next Earnings | 26 Feb 2026 |
|---|
Market Cap | -690M 1.4B |
|---|---|
Previous open | 19.61 |
Previous close | 22.62 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
uniQure NV Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
uniQure NV Forecast
Price Target
By TipRanks
125.18% upside
12 Months Forecast
Average 50.44 USD 125.18%
High 70 USD
Low 33 USD
Based on 11 Wall Street analysts offering 12 month price targets foruniQure NV - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Live chat